{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T17:54:06Z","timestamp":1791914046824,"version":"4.3.4"},"reference-count":43,"publisher":"Public Library of Science (PLoS)","issue":"10","license":[{"start":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T00:00:00Z","timestamp":1791849600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS One"],"abstract":"<jats:sec id=\"sec001\">\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To assess the utilization of ceftazidime-avibactam at Thong Nhat Hospital, a national hospital in Vietnam.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec002\">\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A descriptive cross-sectional study was conducted using retrospective data from medical records of inpatients aged\u2009\u2265\u200918 years who received ceftazidime-avibactam for at least 2 days between January 2023 and March 2025 at Thong Nhat Hospital, Vietnam. The appropriateness of ceftazidime-avibactam use was evaluated based on Thong Nhat Hospital\u2019s antibiotic use guideline. The backward conditional method was used to identify factors associated with patient treatment outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec003\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A total of 101 patients were included, with a median age of 78 years (68\u221286). Respiratory and bloodstream infections were the most common types, accounting for 84.15% and 44.55% of cases, respectively. Gram-negative bacteria comprised 76.05% of isolates, with\n                      <jats:italic>Klebsiella pneumoniae<\/jats:italic>\n                      (26.47%),\n                      <jats:italic>Klebsiella aerogenes<\/jats:italic>\n                      (18.50%) and\n                      <jats:italic>Pseudomonas aeruginosa<\/jats:italic>\n                      (10.50%) being the most frequent. The susceptibility rate to ceftazidime-avibactam was 71.43% for\n                      <jats:italic>Klebsiella pneumoniae<\/jats:italic>\n                      , 95.65% for\n                      <jats:italic>Klebsiella aerogenes<\/jats:italic>\n                      and 42.86% for\n                      <jats:italic>Pseudomonas aeruginosa<\/jats:italic>\n                      . OXA-48 was the most detected carbapenemase gene (37.84%). The overall appropriateness rate of ceftazidime-avibactam use was 70.30%. The treatment success rate was 39.60%. Treatment in the intensive care unit was associated with decreased treatment success, while comorbid heart failure showed a potential association.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec004\">\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The treatment success rate with ceftazidime-avibactam in this study was relatively low. Continuous surveillance of microbiological profiles and antibiotic resistance, particularly to ceftazidime-avibactam, is essential to better guide the management of drug-resistant Gram-negative infections at the hospital.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1371\/journal.pone.0359631","type":"journal-article","created":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T17:32:49Z","timestamp":1791912769000},"page":"e0359631","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":0,"title":["Investigation on the use of ceftazidime-avibactam at a national hospital in Vietnam"],"prefix":"10.1371","volume":"21","author":[{"given":"Khue Dang Minh","family":"Van","sequence":"first","affiliation":[{"name":"University of Medicine and Pharmacy","place":["Ho Chi Minh City, Vietnam"],"department":["Department of Clinical Pharmacy, School of Pharmacy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Han Ngoc Bao","family":"Pham","sequence":"additional","affiliation":[{"name":"University of Medicine and Pharmacy","place":["Ho Chi Minh City, Vietnam"],"department":["Department of Clinical Pharmacy, School of Pharmacy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"An Thi Thanh","family":"Nguyen","sequence":"additional","affiliation":[{"name":"Thong Nhat Hospital","place":["Ho Chi Minh City, Vietnam"],"department":["Department of Pharmacy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nhi Truc Y.","family":"Nguyen","sequence":"additional","affiliation":[{"name":"Thong Nhat Hospital","place":["Ho Chi Minh City, Vietnam"],"department":["Department of Pharmacy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cam Thi Le","family":"Pham","sequence":"additional","affiliation":[{"name":"Thong Nhat Hospital","place":["Ho Chi Minh City, Vietnam"],"department":["Department of Pharmacy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nhan Thi Thanh","family":"Dang","sequence":"additional","affiliation":[{"name":"Thong Nhat Hospital","place":["Ho Chi Minh City, Vietnam"],"department":["Department of Pharmacy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8762-9634","authenticated-orcid":true,"given":"Quynh Thi Huong","family":"Bui","sequence":"additional","affiliation":[{"name":"University of Medicine and Pharmacy","place":["Ho Chi Minh City, Vietnam"],"department":["Department of Clinical Pharmacy, School of Pharmacy"]},{"name":"Thong Nhat Hospital","place":["Ho Chi Minh City, Vietnam"],"department":["Department of Pharmacy"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2026,10,13]]},"reference":[{"key":"pone.0359631.ref001","article-title":"Gram-negative bacterial infections: Research priorities, accomplishments, and future directions of the antibacterial resistance leadership group","volume":"64","author":"Y Doi","year":"2017","journal-title":"Clin Infect Dis"},{"issue":"10325","key":"pone.0359631.ref002","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/S0140-6736(21)02724-0","article-title":"Global burden of bacterial antimicrobial resistance in 2019: A systematic analysis","volume":"399","author":"Antimicrobial Resistance Collaborators","year":"2022","journal-title":"Lancet"},{"issue":"2","key":"pone.0359631.ref003","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1093\/cid\/ciac268","article-title":"Infectious diseases society of America 2022 guidance on the treatment of extended-spectrum \u03b2-lactamase Producing Enterobacterales (ESBL-E), Carbapenem-Resistant Enterobacterales (CRE), and Pseudomonas aeruginosa with Difficult-to-Treat Resistance (DTR-P. aeruginosa)","volume":"75","author":"PD Tamma","year":"2022","journal-title":"Clin Infect Dis"},{"key":"pone.0359631.ref004","author":"National Healthcare Safety Network C for DC and Prevention","year":"2016"},{"key":"pone.0359631.ref005","volume-title":"Guidelines for antibiotic use","author":"BTH Quynh","year":"2022"},{"issue":"5","key":"pone.0359631.ref006","first-page":"70","article-title":"Antibiotic susceptibility of common bacterial species causing bloodstream infections isolated at Bach Mai Hospital in 2023","volume":"178","author":"PH Nhung","year":"2024","journal-title":"J Med Res"},{"issue":"7","key":"pone.0359631.ref007","article-title":"Antibiotic resistance of hospital-acquired infection pathogens in the department of infectious diseases intensive care at 108 military central hospital from January 2024 to September 2024","volume":"19","author":"NS Thau","year":"2024","journal-title":"J Clin Med Pharm"},{"issue":"1","key":"pone.0359631.ref008","first-page":"32","article-title":"Burden and resistance of Gram-negative pathogens in ICU-acquired infections in Vietnam: A cross-sectional study","volume":"18","author":"DQ Phong","year":"2026","journal-title":"Iran J Microbiol"},{"key":"pone.0359631.ref009","article-title":"Investigation on the use of ceftazidime-avibactam and ceftolozane-tazobactam at the University of Medicine and Pharmacy, Ho Chi Minh City","volume":"1","author":"NDT Phan","year":"2025","journal-title":"Y HOC TP HO CHI MINH"},{"key":"pone.0359631.ref010","article-title":"BMI classification percentile and cut off points","volume-title":"StatPearls","author":"CB Weir","year":"2024"},{"key":"pone.0359631.ref011","unstructured":"Zavicefta 2 g\/0.5 g powder for concentrate for solution for infusion. 2022."},{"issue":"4","key":"pone.0359631.ref012","doi-asserted-by":"crossref","first-page":"560","DOI":"10.4103\/ijcm.IJCM_16_20","article-title":"Errors in the use of multivariable logistic regression analysis: An empirical analysis","volume":"45","author":"RK Malhotra","year":"2020","journal-title":"Indian J Community Med"},{"issue":"6","key":"pone.0359631.ref013","doi-asserted-by":"crossref","first-page":"558","DOI":"10.4097\/kja.19087","article-title":"Multicollinearity and misleading statistical results","volume":"72","author":"JH Kim","year":"2019","journal-title":"Korean J Anesthesiol"},{"issue":"12","key":"pone.0359631.ref014","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.4103\/indianjpsychiatry.indianjpsychiatry_827_23","article-title":"Firth\u2019s penalized logistic regression: A superior approach for analysis of data from India\u2019s National Mental Health Survey, 2016","volume":"65","author":"S Suhas","year":"2023","journal-title":"Indian J Psychiatry"},{"issue":"6","key":"pone.0359631.ref015","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1016\/j.jsps.2023.03.019","article-title":"Assessment of risk factors associated with multidrug-resistant organism infections among patients admitted in a tertiary hospital - A retrospective study","volume":"31","author":"AF Alsehemi","year":"2023","journal-title":"Saudi Pharm J"},{"issue":"2","key":"pone.0359631.ref016","doi-asserted-by":"crossref","first-page":"105036","DOI":"10.1016\/j.idnow.2025.105036","article-title":"Real-world use, effectiveness, and safety of ceftazidime-avibactam: Results of the French cohort OZAVIE","volume":"55","author":"L Piroth","year":"2025","journal-title":"Infect Dis Now"},{"issue":"12","key":"pone.0359631.ref017","article-title":"Real-world experience with Ceftazidime-Avibactam for multidrug-resistant gram-negative bacterial infections","volume":"6","author":"SCJ Jorgensen","year":"2019","journal-title":"Open Forum Infect Dis"},{"key":"pone.0359631.ref018","unstructured":"Calvo-Garcia A, Urriaga IBZ, Ram\u00edrezherr\u00e1iz E, P\u00e9rezab\u00e1nades M, S\u00e1ezb\u00e9jar C, Aladr\u00f3n MOB, et al. Ceftazidime-avibactam: effectiveness and safety in the clinical practice. A third hospital level experience. 2020."},{"issue":"6","key":"pone.0359631.ref019","doi-asserted-by":"crossref","first-page":"102735","DOI":"10.1016\/j.jiph.2025.102735","article-title":"Real-world use and treatment outcomes of ceftazidime-avibactam in gram-negative bacterial infection in Taiwan: A multicenter retrospective study","volume":"18","author":"T-Y Yang","year":"2025","journal-title":"J Infect Public Health"},{"issue":"49","key":"pone.0359631.ref020","first-page":"19","article-title":"Efficacy of ceftazidime-avibactam in the treatment of bacterial secondary infection in COVID-19 patients at Hospital for Tropical Diseases","volume":"1","author":"HQ Minh","year":"2025","journal-title":"Vietnam J Infect Diseases"},{"issue":"5","key":"pone.0359631.ref021","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1093\/jac\/dkac049","article-title":"Impact of ceftazidime\/avibactam versus best available therapy on mortality from infections caused by carbapenemase-producing Enterobacterales (CAVICOR study)","volume":"77","author":"JJ Cast\u00f3n","year":"2022","journal-title":"J Antimicrob Chemother"},{"issue":"3","key":"pone.0359631.ref022","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1007\/s40121-023-00762-9","article-title":"The use and effectiveness of ceftazidime-avibactam in real-world clinical practice: EZTEAM study","volume":"12","author":"A Soriano","year":"2023","journal-title":"Infect Dis Ther"},{"issue":"2","key":"pone.0359631.ref023","article-title":"Antimicrobial susceptibility of Pseudomonas aeruginosa strains causing pneumonia in the intensive care unit of Bach Mai Hospital, 2024","volume":"547","author":"NH Nam","year":"2025","journal-title":"Vietnam Med J"},{"issue":"1","key":"pone.0359631.ref024","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1186\/s13756-021-00937-4","article-title":"Antimicrobial susceptibility testing results from 13 hospitals in Viet Nam: VINARES 2016\u20132017","volume":"10","author":"VINARES consortium","year":"2021","journal-title":"Antimicrob Resist Infect Control"},{"key":"pone.0359631.ref025","volume-title":"Situation analysis: antibiotic use and resistance in Vietnam","author":"GARP-Vietnam National Working Group","year":"2010"},{"issue":"11","key":"pone.0359631.ref026","doi-asserted-by":"crossref","first-page":"113844","DOI":"10.1016\/j.isci.2025.113844","article-title":"Exposure to ceftazidime-avibactam induced antimicrobial resistance and enhanced virulence in a Klebsiella pneumoniae strain","volume":"28","author":"J Li","year":"2025","journal-title":"iScience"},{"issue":"8","key":"pone.0359631.ref027","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00779-19","article-title":"Evaluation of the synergy of ceftazidime-avibactam in combination with meropenem, amikacin, aztreonam, colistin, or fosfomycin against well-characterized multidrug-resistant Klebsiella pneumoniae and Pseudomonas aeruginosa","volume":"63","author":"S Mikhail","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"pone.0359631.ref028","doi-asserted-by":"crossref","DOI":"10.1128\/CMR.00031-19","article-title":"Epidemiology and treatment of multidrug-resistant and extensively drug-resistant Pseudomonas aeruginosa infections","volume":"32","author":"JP Horcajada","year":"2019","journal-title":"Clin Microbiol Rev"},{"issue":"3","key":"pone.0359631.ref029","doi-asserted-by":"crossref","DOI":"10.1016\/S2666-5247(22)00329-9","article-title":"Global epidemiology and clinical outcomes of carbapenem-resistant Pseudomonas aeruginosa and associated carbapenemases (POP): A prospective cohort study","volume":"4","author":"J Reyes","year":"2023","journal-title":"Lancet Microbe"},{"issue":"6","key":"pone.0359631.ref030","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.3201\/eid2406.171648","article-title":"Genomic epidemiology of global carbapenemase-producing Enterobacter spp., 2008\u20132014","volume":"24","author":"G Peirano","year":"2018","journal-title":"Emerg Infect Dis"},{"issue":"5","key":"pone.0359631.ref031","first-page":"61","article-title":"Antibiotic susceptibility and carbapenemase gene profiles of Pseudomonas aeruginosa isolates at Hanoi Medical University Hospital, 2019-2022","volume":"178","author":"NT Anh","year":"2024","journal-title":"J Med Res"},{"key":"pone.0359631.ref032","doi-asserted-by":"crossref","DOI":"10.1093\/cid\/ciz824","article-title":"Epidemiology and diagnostics of carbapenem resistance in gram-negative bacteria","volume":"69","author":"P Nordmann","year":"2019","journal-title":"Clin Infect Diseases"},{"issue":"1","key":"pone.0359631.ref033","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1186\/s13756-021-00950-7","article-title":"Molecular epidemiology of carbapenem-resistant Enterobacterales in Thailand, 2016\u20132018","volume":"10","author":"W Paveenkittiporn","year":"2021","journal-title":"Antimicrob Resist Infect Control"},{"issue":"2","key":"pone.0359631.ref034","doi-asserted-by":"crossref","first-page":"285","DOI":"10.4103\/ijmr.IJMR_36_18","article-title":"Molecular epidemiology and therapeutic options of carbapenem-resistant Gram-negative bacteria","volume":"149","author":"A Garg","year":"2019","journal-title":"Indian J Med Res"},{"key":"pone.0359631.ref035","article-title":"Real-world evidence on use of ceftazidime-avibactam in the management of gram-negative infections: A retrospective analysis","author":"S Todi","year":"2024","journal-title":"Cureus"},{"issue":"3","key":"pone.0359631.ref036","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1093\/jac\/dkac439","article-title":"Pharmacokinetics\/pharmacodynamics and therapeutic drug monitoring of ceftazidime\/avibactam administered by continuous infusion in patients with MDR Gram-negative bacterial infections","volume":"78","author":"D Fresan","year":"2023","journal-title":"J Antimicrob Chemother"},{"issue":"11","key":"pone.0359631.ref037","doi-asserted-by":"crossref","DOI":"10.1128\/aac.00969-23","article-title":"Could an optimized joint pharmacokinetic\/pharmacodynamic target attainment of continuous infusion ceftazidime-avibactam be a way to avoid the need for combo therapy in the targeted treatment of deep-seated DTR Gram-negative infections?","volume":"67","author":"M Gatti","year":"2023","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"pone.0359631.ref038","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/j.ccc.2013.03.016","article-title":"Infections in the elderly","volume":"29","author":"HJ Hepper","year":"2013","journal-title":"Crit Care Clin"},{"issue":"4","key":"pone.0359631.ref039","doi-asserted-by":"crossref","DOI":"10.31436\/imjm.v22i4.2272","article-title":"Carbapenem-resistant Enterobacteriaceae Bacteraemia in intensive care unit: A descriptive study on risk factors and clinical outcome","volume":"22","author":"S Nachamuthu","year":"2023","journal-title":"IMJM"},{"issue":"2","key":"pone.0359631.ref040","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.cmi.2020.10.016","article-title":"Risk factors for carbapenem-resistant Gram-negative bacterial infections: A systematic review","volume":"27","author":"ZR Palacios-Baena","year":"2021","journal-title":"Clin Microbiol Infect"},{"key":"pone.0359631.ref041","first-page":"35","article-title":"Comorbidities in heart failure.","author":"HH Van Der Wal","year":"2017","journal-title":"Heart failure"},{"issue":"3","key":"pone.0359631.ref042","doi-asserted-by":"crossref","first-page":"285","DOI":"10.3390\/antibiotics13030285","article-title":"Antimicrobial and diagnostic stewardship of the novel \u03b2-lactam\/\u03b2-lactamase inhibitors for infections due to carbapenem-resistant Enterobacterales species and Pseudomonas aeruginosa","volume":"13","author":"S Ferous","year":"2024","journal-title":"Antibiotics (Basel)"},{"issue":"4","key":"pone.0359631.ref043","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1007\/s40121-021-00507-6","article-title":"Ceftazidime-Avibactam for the treatment of serious gram-negative infections with limited treatment options: A systematic literature review","volume":"10","author":"A Soriano","year":"2021","journal-title":"Infect Dis Ther"}],"container-title":["PLOS One"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0359631","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T17:32:57Z","timestamp":1791912777000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0359631"}},"subtitle":[],"editor":[{"given":"Sahjid","family":"Mukhida","sequence":"first","affiliation":[{"name":"Dr D Y Patil Vidyapeeth University Dr D Y Patil Medical College Hospital and Research Centre: Dr D Y Patil Medical College Hospital and Research Centre","place":["INDIA"]}],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2026,10,13]]},"references-count":43,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2026,10,13]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0359631","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,13]]}}}